Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Clinical trial NCT04744116 · RECRUITING

Trial details

NCT number: NCT04744116
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Hematopoietic and Lymphoid Cell Neoplasm Steroid Refractory Graft Versus Host Disease

Start date: 2021-02-17
Primary completion: 2032-03-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.